cpx-351 with venetoclax in r/r aml: results of a phase ib study
Published 7 months ago • 53 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
5:03
combining venetoclax with cpx-351 for aml
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
5:55
promise of recently approved agents for aml: cpx-351
-
5:50
to what extent can cpx-351 contribute to long-term remissions in high-risk aml?
-
7:08
what does real-world data tell us about frontline therapy with cpx-351 vs ven aza?
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
2:21
cpx-351 for high-risk aml
-
3:03
cpx-351 vs. hma plus venetoclax in the treatment of patients with aml
-
1:55
cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
-
1:22
the benefit of cpx-351 over 7 3 in patients with saml by baseline bone marrow percentage
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
3:20
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
1:48
updates on cpx-351: real world experiences and studies in mds
-
1:26
low bone marrow cellularity predicts hematologic aes to cpx-351 in aml